Rivercyte wins Phase 1 of the Bavarian Business Plan Competition
2025-02-12Rivercyte has been recognized as one of the winning teams in Phase 1 of the Business Plan Competition Northern Bavaria 2025. This achievement underscores the potential of our technology in the healthcare sector.
We are thrilled to announce that Rivercyte has been selected as one of the winners in Phase 1 of the Business Plan
Competition Northern Bavaria 2025, organized by BayStartUP.
This recognition marks an important milestone in our journey to revolutionize
infection diagnostics using high-throughput microscopy, AI-based image analysis,
and microfluidics. Our deformability cytometry technology enables the rapid assessment of blood cell deformability from just a single drop of blood,
offering a groundbreaking solution for early infection detection. Winning Phase 1 validates the potential of Rivercyte's technology,
supporting us on our endeavour to improve clinical diagnostics.
The Business Plan Competition Northern Bavaria is a program supporting innovative startups across various industries.
It provides participating teams with valuable feedback, expert mentoring, and networking opportunities with investors and industry leaders.
The competition is structured in three phases, allowing startups to refine their business concepts and strategies progressively.
More details about the competition and the winners can be found on the
website of BayStartUP.
Rivercyte team receiving the prize from BayStartUP. © BayStartUP/Bert Willer
Rivercyte and the participants of Startup Demo Night Nürnberg.